Pliant Therapeutics presents RNA delivery platform targeting skeletal and cardiac muscle
PLRX•Pliant Therapeutics said it is advancing RNA delivery programs toward investigational new drug applications for selected neuromuscular diseases and rare cardiomyopathies. In preclinical studies, its programs demonstrated muscle gene knockdown, and PLN-753-siMSTN combined with tirzepatide preserved lean mass and enhanced fat loss.
1. Preclinical program results
Pliant Therapeutics said PLN-662 demonstrated skeletal and cardiac muscle target gene knockdown in mice and nonhuman primates after subcutaneous dosing. PLN-753 achieved durable, selective skeletal muscle gene knockdown in mice after a single low subcutaneous dose.
2. Combination study
In a preclinical study, PLN-753-siMSTN combined with tirzepatide preserved lean mass and enhanced fat loss. The company is advancing its integrin-targeted RNA delivery programs toward investigational new drug applications for selected neuromuscular diseases and rare cardiomyopathies.
